# Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

> **NCT07093710** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 101 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib
- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT07093710
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2027-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093710, "Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07093710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*